1. Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation
by Koichi Miyamura, Kazunori Ohnishi, Shigeki Ohtake, Noriko Usui, Chiaki Nakaseko, Hiroyuki Fujita, Shin Fujisawa, Toru Sakura, Hirokazu Okumura, Noriyoshi Iriyama, Nobuhiko Emi, Katsumichi Fujimaki, Sumihisa Honda, Yasushi Miyazaki, and Tomoki Naoe
BloodAdv
Volume 3(3):
February 12, 2019
© 2019 by The American Society of Hematology

2. Koichi Miyamura et al. Blood Adv 2019;3:312-319
© 2019 by The American Society of Hematology

3. Design of JALSG CML207 phase 3 study.
Design of JALSG CML207 phase 3 study. IM, imatinib.
Koichi Miyamura et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

4. Molecular response.
Molecular response. Rates of MR3 at 12 and 24 months. The results in the ITT population were calculated using the Cochran–Mantel–Haenszel test.
Koichi Miyamura et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

5. Cumulative incidence of MR3.
Cumulative incidence of MR3. Kaplan-Meier estimates of the time to the first MR3. All time-to-event comparisons in the ITT were performed using the log-rank test, stratified according to Sokal risk group. Solid and dashed lines indicate groups B and A, respectively.
Koichi Miyamura et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

6. Results of dose escalation.
Results of dose escalation. (A) The proportion of protocol compliance at 3 and 6 months. Patients who did not receive cytogenetic or molecular tests properly were excluded. (B) Levels of molecular remission according to dose escalation status. The left bar shows the result of 29 patients who did not need to increase at 3 months and 6 months. The middle bar represents the 42 patients who accurately increased their dose of imatinib at 3 months and 6 months in accordance with the protocol. The right bar shows the outcome in the 40 patients who failed to increase their dose of imatinib at 3 months or 6 months according to the protocol. Three patients (corresponding to the middle bar) and 5 patients (corresponding to right bar) who did not have a molecular response test at 12 months were excluded from this analysis.
Koichi Miyamura et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

7. Rate of survival.
Rate of survival. (A) OS. (B) Progression/failure-free survival.
Koichi Miyamura et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology